Status:
UNKNOWN
Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients With COVID-19
Lead Sponsor:
Azienda Ospedaliera Universitaria Integrata Verona
Conditions:
COVID-19
Thrombosis Pulmonary
Eligibility:
All Genders
18-99 years
Phase:
PHASE3
Brief Summary
Inflammatory diseases favour the onset of venous thromboembolic events in hospitalized patients. Thromboprophylaxis with a fixed dose of heparin/low molecular weight heparin (LMWH) is recommended if c...
Detailed Description
Severe respiratory failure and multi-organ damage in coronavirus disease 2019 (COVID-19) patients have not a unitary pathophysiological interpretation. There is evidence of an association between the ...
Eligibility Criteria
Inclusion
- in a medical area ward dedicated to Covid-19 patients
- Positivity by RT\_PCR of the search for genetic material of SARS-CoV2
- Covid-19 pneumonia with moderate clinical picture based on clinical parameters
- O2 saturation\> 94% with maximum FiO2 32%
- Respiratory acts \<30 / minute
- age \>18 years
- Consent to participate in the study
Exclusion
- Any Antithrombotic treatment including acetylsalicylic acid
- Active Bacterial infection
- Active or in maintenance therapy neoplasm
- Inability to provide consent
- Any contraindication to the acetylsalicylic acid use
- Active peptic disease
- Active Major pathological bleeding
- Recent (\<30 days) major bleeding
- Recent intracranial bleeding
- Need to use therapeutic doses of oral anticoagulants or heparins
- Need to use combination antiplatelet drugs for clinical indication
- Hypersensitivity to acetylsalicylic acid or to any of the excipients
- Hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs)
- Severe hepatic insufficiency (Child-Pugh class C).
- Severe heart failure (NYHA class 3-4)
- Platelet count less than 150000 / mmc
- Haemostasis alteration (INR\> 1.5, APTT\> 1.5)
- Plasma fibrinogen \<100 mg / dL
- Blood pressure \>160/100 mmHg
- Concomitant treatment with serotonin reuptake inhibitors
- Participation in another pharmacological clinical trial
Key Trial Info
Start Date :
April 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2021
Estimated Enrollment :
204 Patients enrolled
Trial Details
Trial ID
NCT04808895
Start Date
April 1 2021
End Date
August 31 2021
Last Update
March 22 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Azienda Ospedaliera Universitaria Integrata Verona
Verona, Italy, 37126